Abstract. To (75 g), a clear and sustained rise in plasma SLI was seen in normal subjects from an initial value (\ m=+-\sem) of 29.9 \ m=+-\5.4 pg/ml to a peak value, at 60 min of 93.4 \ m=+-\15.5 pg/ml. The increase of plasma SLI after 75 g glucose was also observed in IDDM and NIDDM. The peak level of SLI was significantly less than that for normal subjects. The extraction of plasma SLI with acetic acid and acetone gave reproducible results and showed a fluctuation of SLI with glucose concentration.
Abstract. To study the role of somatostatin in the pathophysiology of glucose intolerance in man, plasma somatostatin-like immunoreactivity (SLI) was measured in 8 normal subjects, 6 patients with insulin dependent diabetes mellitus (IDDM), 13 with non-insulin dependent diabetes mellitus (NIDDM), and 9 with hyperthyroidism, by extraction of plasma SLI and radioimmunoassay. The extraction method gave a recovery rate for synthetic somatostatin-14 and somatostatin-28 of 72 \m=+-\6 and 55 \ m=+-\ 7%, respectively. No SLI corresponding to somatostatin\x=req-\ 28 in human peripheral blood was observed. Incubation of somatostatin-28 in plasma gave a rapid decrease of immunoreactivity, and no conversion to somatostatin-14 was observed. It is speculated that SLI extracted with acid-acetone mainly represents a molecular weight similar to somatostatin-14. After oral administration of glucose (75 g), a clear and sustained rise in plasma SLI was seen in normal subjects from an initial value (\ m=+-\sem) of 29.9 \ m=+-\5.4 pg/ml to a peak value, at 60 min of 93.4 \ m=+-\15.5 pg/ml. The increase of plasma SLI after 75 g glucose was also observed in IDDM and NIDDM. The peak level of SLI was significantly less than that for normal subjects. (Itoh et al. 1980) suggests an important function in glucose homeo¬ stasis. Somatostatin is also located in the gastro¬ intestinal tract and has a suppressive function on motility and absorption (Gerich 1981 (Schusdziarra et al. 1977) as well as in vitro (Hara et al. 1979 ), but there are no studies in human diabetics. The measurement of somatostatin in human blood has several difficul¬ ties, related to degradation in blood (Benuck & Marks 1976) , size heterogeneity (Mackes et al. 1981) , and a non-specific plasma inhibition of the radioimmunoassay Mackes et al. 1981) . A few reports from human studies sug¬ gest that somatostatin-like immunoreactivity (SLI) in plasma is increased by several stimulants such as arginine (Saito & Saito 1982) , glucose (Wass et al. 1980) , hypoglycaemia (Vinik et al. 1981) , and meals (Wass et al. 1980; Vinik et al. 1981 
Materials and Methods
The study subjects consisted of 8 healthy non-obese controls (7 men and 1 woman, aged [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] 
Results
Gel filtration ofplasma SLI (Fig. 1) The elution profiles of plasma SLI following gel filtration of extracted plasma are given in Fig. 1 (-) and NIDDM (-) . Hatched area indicates mean ± SEM of normal subjects. peak of SLI in NIDDM was observed at 90 min and the level was still higher than the pre-stimulatory level in NIDDM. However, the peak of SLI was significantly less than that of normal subjects.
Response of SLI to 75 g OGTT in hyperthyroidism (Fig. 5 Glucose is known to be a potent stimulant of SLI from studies in animal pancreas and duodenum in vitro (Schauder et al. 1976; Ipp et al. 1977) as well as in vivo (Schusdziarra et al. 1977; Utsumi et al. 1979 ). The present study confirms the report that glucose administration increases plasma SLI meas¬ ured in man using a different extraction method (Wass et al. 1980 (Hara et al. 1979 ) and dog (Schusdziarra et al. 1977) , the release of SLI from the pancreas and gastro-intestinal tract was in¬ creased in vitro. In the present studies, the re¬ sponse of plasma SLI to an oral glucose load in both IDDM and NIDDM was not augmented but rather blunted. The reason for these discrepancies remains uncertain, but they may be explained by difference of species and experimental conditions (in vitro vs in vivo). A lower response of SLI to insulin-induced hypoglycaemia has also been re¬ ported in NIDDM (Vinik et al. 1981) . The patho¬ genesis of impaired glucose tolerance in hyper¬ thyroidism is a matter of dispute. A rapid increase of glucose absorption (Holdsworth & Besser 1968) , antagonistic action of thyroid hormone to insulin (Doar et al. 1968) , increased glucose turnover (Perez et al. 1980 ) have all been proposed. No significant difference between the patients with hyperthyroidism and normal subjects was observed as far as SLI was concerned. The increase of SLI might be secondary to other events produced by glucose, since it appears late after the administra¬ tion of glucose. However, this increase of SLI seems to be independent of an increase in insulin (Fig. 4) . The gastro-intestinal hormones and cate-cholamines may also influence plasma SLI, but further investigations are awaited.
Recently, a 28-amino acid N-terminally extended somatostatin has been isolated from gut (Pradayrol et al. 1980) , hypothalamus ) and pancreas . Its biological role remains to be determined, although this peptide has been reported to be more potent on a molar basis than somatostatin-14 in inhibiting growth hormone 
